Symbols / GILD Stock $134.94 +1.06% Gilead Sciences, Inc.

Healthcare • Drug Manufacturers - General • United States • NMS
GILD (Stock) Chart
O: — H: — L: — C: — V: —
SMA 20: — SMA 50: — SMA 200: —
Stock Fundamentals
Scroll to Statements
Index EQUITY
Sector Healthcare
Industry Drug Manufacturers - General
CEO Mr. Daniel P. O'Day
Exch · Country NMS · United States
Market Cap 167.54B
Enterprise Value 179.81B
Income 9.22B
Sales 29.74B
FCF (ttm) 7.93B
Book/sh 18.29
Cash/sh 7.91
Employees 17,000
Insider 10d —
IPO Jan 22, 1992
Div forward ($/yr)
Div TTM ($/yr)
Dividend Yield
Ex-Div Date
5Y Avg Yield
Yield vs 5Y Avg
Payout 43.40%
P/E 18.36
Forward P/E 13.93
PEG 0.37
P/S 5.63
P/B 7.38
P/C —
EV/EBITDA 12.20
EV/Sales 6.05
Quick Ratio 1.54
Current Ratio 1.97
Debt/Eq 94.64
LT Debt/Eq —
EPS (ttm) 7.35
EPS next Y 9.68
EPS Growth 54.80%
Revenue Growth 4.40%
EPS Gr Q/Q 53.70%
Rev Gr Q/Q —
Earnings (next) 2026-08-06
Earnings (prior) 2026-05-07
ROA 13.29%
ROE 43.36%
ROIC —
Gross Margin 79.37%
Oper. Margin 39.28%
Profit Margin 30.99%
Shs Outstand 1.24B
Shs Float 1.24B
Insider Own 0.13%
Instit Own 92.12%
Short Float 1.86%
Short Ratio 4.22
Short Interest 23.05M
52W High 157.29
vs 52W High -14.21%
52W Low 97.86
vs 52W Low 37.89%
Beta 0.33
Impl. Vol. 39.03%
Rel Volume 0.97
Avg Volume 6.20M
Volume 6.03M
Target (mean) $157.96
Tgt Median $160.50
Tgt Low $122.00
Tgt High $180.00
# Analysts 28
Recom Buy
Prev Close $133.52
Price $134.94
Change 1.06%
About

Gilead Sciences, Inc., a biopharmaceutical company, discovers, develops, and commercializes medicines in the areas of unmet medical need in the United States, Europe, and internationally. The company provides Biktarvy, Descovy, Genvoya, Odefsey, Sunlenca, Symtuza, and YeztugoFor the treatment of HIV-1 infection in patients. It also provides Epclusa, Livdelzi, and Vemlidy to treat chronic hepatitis C virus, primary biliary cholangitis, and chronic hepatitis B virus; Tecartus, a T-cell therapy for the treatment of adult patients; Trodelvy, an injection for intravenous use; and Yescarta, a suspension for intravenous infusion, is a CAR T-cell therapy for the treatment of adult patients. Further, it provides AmBisome, for the treatment of serious invasive fungal infections; and Veklury for the treatment of COVID-19. Additionally, the company engages in the development of various immunotherapies for patients with cancer and other incurable diseases. The company has collaboration agreements with Shenzhen Pregene Biopharma Co., Ltd.; Abingworth; Arcus Biosciences, Inc.; Merck Sharp & Dohme Corp.; Janssen Sciences Ireland Unlimited Company; Japan Tobacco, Inc.; Everest Medicines; Merck & Co, Inc.; Tentarix Biotherapeutics Inc.; and Assembly Biosciences, Inc. It also has research collaboration, option, and license agreement with Merus N.V. for the discovery of novel dual tumor-associated antigens (TAA) targeting trispecific antibodies. The company has a collaboration with Terray Therapeutics, Inc. to discover and develop small molecule therapies; and LEO Pharma to develop, manufacture, and commercialize the small molecule oral STAT6 program. The company was incorporated in 1987 and is headquartered in Foster City, California.

Valuation Models

Price estimates from analyst targets and simple models.

1. Analyst consensus
$157.96
Mean price target
2. Current target
$134.94
Latest analyst target
3. DCF / Fair value
$115.03
Simplified: (Free Cash Flow ÷ Shares) × 18 (P/FCF multiple). Not a …
Ratings
Current target
$134.94
Low
$122.00
High
$180.00
Mean
$157.96

Latest analyst rating changes

Date Action Analyst Rating Change Price Target
2026-05-08 reit Truist Securities Buy → Buy $157
2026-05-08 main RBC Capital Sector Perform → Sector Perform $122
2026-04-13 main Citigroup Buy → Buy $165
2026-04-10 main Morgan Stanley Overweight → Overweight $175
2026-03-10 init Jefferies — → Buy $180
2026-02-23 reit Needham Buy → Buy $170
2026-02-20 init Barclays — → Equal-Weight $155
2026-02-11 main RBC Capital Sector Perform → Sector Perform $118
2026-02-11 main Truist Securities Buy → Buy $152
2026-02-11 main Wells Fargo Overweight → Overweight $165
2026-02-11 main Cantor Fitzgerald Overweight → Overweight $155
2026-02-11 main Scotiabank Sector Outperform → Sector Outperform $177
2026-02-11 main Needham Buy → Buy $170
2026-01-27 main Truist Securities Buy → Buy $145
2026-01-27 main Citigroup Buy → Buy $156
2026-01-26 main UBS Buy → Buy $155
2026-01-13 main Morgan Stanley Overweight → Overweight $150
2026-01-07 main Citigroup Buy → Buy $140
2025-12-12 main Morgan Stanley Overweight → Overweight $151
2025-12-10 main Wells Fargo Overweight → Overweight $150
News
RSS: Latest GILD news
Insider Transactions
Filed Date Insider Relationship Transaction Shares Price Value SEC
2026-04-30 RODRIGUEZ JAVIER Director — 1,146 $0.00 $0
2026-04-30 HORNING SANDRA Director — 1,146 $0.00 $0
2026-04-30 LOVE TED WENDELL Director — 1,146 $0.00 $0
2026-04-30 BLUESTONE JEFFREY Director — 1,146 $0.00 $0
2026-04-30 MANWANI HARISH Director — 1,146 $0.00 $0
2026-04-30 BARTON JACQUELINE K Director — 1,146 $0.00 $0
2026-04-30 WELTERS ANTHONY Director — 1,146 $0.00 $0
2026-04-28 O'DAY DANIEL PATRICK Chief Executive Officer — 10,000 $128.79 $1,291,608
2026-04-15 MERCIER JOHANNA Officer — 3,000 $140.96 $422,880
2026-04-15 DICKINSON ANDREW D Chief Financial Officer — 3,000 $140.96 $422,880
Financials
Statement View
Amounts in millions (2 decimals, no suffix) • EPS per share (2 decimals) • Trend = period evolution • YoY Growth = previous period %
Line Item Trend 2025-12-31 2024-12-31 2023-12-31 2022-12-31
Total Revenue
29,442.00
+2.39%
28,754.00
+6.04%
27,116.00
-0.60%
27,281.00
Operating Revenue
29,442.00
+2.39%
28,754.00
+6.04%
27,116.00
-0.60%
27,281.00
Cost Of Revenue
6,234.00
-0.27%
6,251.00
-3.80%
6,498.00
+14.87%
5,657.00
Reconciled Cost Of Revenue
6,234.00
-0.27%
6,251.00
-3.80%
6,498.00
+14.87%
5,657.00
Gross Profit
23,208.00
+3.13%
22,503.00
+9.14%
20,618.00
-4.65%
21,624.00
Operating Expense
11,507.00
-3.36%
11,907.00
+1.08%
11,780.00
+10.61%
10,650.00
Research And Development
5,799.00
-1.83%
5,907.00
+3.31%
5,718.00
+14.89%
4,977.00
Selling General And Administration
5,708.00
-4.87%
6,000.00
-1.02%
6,062.00
+6.86%
5,673.00
Selling And Marketing Expense
3,522.00
+2.00%
3,453.00
+5.53%
3,272.00
—
General And Administrative Expense
2,186.00
-14.17%
2,547.00
-8.71%
2,790.00
—
Other Gand A
2,186.00
-14.17%
2,547.00
-8.71%
2,790.00
—
Total Expenses
17,741.00
-2.30%
18,158.00
-0.66%
18,278.00
+12.09%
16,307.00
Operating Income
11,701.00
+10.43%
10,596.00
+19.89%
8,838.00
-19.46%
10,974.00
Total Operating Income As Reported
10,022.00
+503.01%
1,662.00
-78.15%
7,605.00
+3.75%
7,330.00
EBITDA
13,580.00
+206.27%
4,434.00
-57.76%
10,496.00
+18.57%
8,852.00
Normalized EBITDA
14,809.00
+8.55%
13,642.00
+14.68%
11,896.00
-9.56%
13,153.00
Reconciled Depreciation
2,760.00
-0.25%
2,767.00
+2.75%
2,693.00
+28.06%
2,103.00
EBIT
10,820.00
+549.07%
1,667.00
-78.64%
7,803.00
+15.62%
6,749.00
Total Unusual Items
-1,229.00
+86.65%
-9,208.00
-557.71%
-1,400.00
+67.45%
-4,301.00
Total Unusual Items Excluding Goodwill
-1,229.00
+86.65%
-9,208.00
-557.71%
-1,400.00
+67.45%
-4,301.00
Special Income Charges
-1,680.00
+81.20%
-8,934.00
-624.57%
-1,233.00
+66.16%
-3,644.00
Other Special Charges
1,024.00
-78.04%
4,663.00
+303.72%
1,155.00
+22.35%
944.00
Restructuring And Mergern Acquisition
66.00
-27.47%
91.00
+225.00%
28.00
—
Write Off
590.00
-85.89%
4,180.00
+8260.00%
50.00
-98.15%
2,700.00
Net Income
8,510.00
+1672.92%
480.00
-91.53%
5,665.00
+23.37%
4,592.00
Pretax Income
9,796.00
+1319.71%
690.00
-89.94%
6,859.00
+17.97%
5,814.00
Net Non Operating Interest Income Expense
-675.00
+3.02%
-696.00
-22.54%
-568.00
+31.48%
-829.00
Interest Expense Non Operating
1,024.00
+4.81%
977.00
+3.50%
944.00
+0.96%
935.00
Net Interest Income
-675.00
+3.02%
-696.00
-22.54%
-568.00
+31.48%
-829.00
Interest Expense
1,024.00
+4.81%
977.00
+3.50%
944.00
+0.96%
935.00
Interest Income Non Operating
349.00
+24.20%
281.00
-25.27%
376.00
+254.72%
106.00
Interest Income
349.00
+24.20%
281.00
-25.27%
376.00
+254.72%
106.00
Other Income Expense
-1,230.00
+86.64%
-9,210.00
-552.73%
-1,411.00
+67.41%
-4,330.00
Other Non Operating Income Expenses
-1.00
+50.00%
-2.00
+81.82%
-11.00
+62.07%
-29.00
Gain On Sale Of Security
451.00
+264.60%
-274.00
-64.07%
-167.00
+74.58%
-657.00
Tax Provision
1,286.00
+509.48%
211.00
-83.08%
1,247.00
-0.08%
1,248.00
Tax Rate For Calcs
0.00
-57.07%
0.00
+68.02%
0.00
-15.21%
0.00
Tax Effect Of Unusual Items
-161.34
+94.27%
-2,815.78
-1005.09%
-254.80
+72.40%
-923.23
Net Income Including Noncontrolling Interests
8,510.00
+1672.92%
480.00
-91.45%
5,613.00
+22.93%
4,566.00
Net Income From Continuing Operation Net Minority Interest
8,510.00
+1672.92%
480.00
-91.53%
5,665.00
+23.37%
4,592.00
Net Income From Continuing And Discontinued Operation
8,510.00
+1672.92%
480.00
-91.53%
5,665.00
+23.37%
4,592.00
Net Income Continuous Operations
8,510.00
+1676.62%
479.00
-91.46%
5,612.00
+22.91%
4,566.00
Minority Interests
0.00
0.00
-100.00%
52.00
+100.00%
26.00
Normalized Income
9,577.66
+39.37%
6,872.22
+0.91%
6,810.20
-14.55%
7,969.77
Net Income Common Stockholders
8,510.00
+1672.92%
480.00
-91.53%
5,665.00
+23.37%
4,592.00
Diluted EPS
6.78
+1684.21%
0.38
-91.56%
4.50
+23.63%
3.64
Basic EPS
6.84
+1700.00%
0.38
-91.63%
4.54
+24.04%
3.66
Basic Average Shares
1,244.00
-0.24%
1,247.00
-0.08%
1,248.00
-0.56%
1,255.00
Diluted Average Shares
1,255.00
+0.00%
1,255.00
-0.24%
1,258.00
-0.32%
1,262.00
Diluted NI Availto Com Stockholders
8,510.00
+1672.92%
480.00
-91.53%
5,665.00
+23.37%
4,592.00
Line Item Trend 2023-12-31
Total Assets
62,125.00
Current Assets
16,085.00
Cash Cash Equivalents And Short Term Investments
7,264.00
Cash And Cash Equivalents
6,085.00
Other Short Term Investments
1,179.00
Receivables
4,660.00
Accounts Receivable
4,660.00
Gross Accounts Receivable
5,495.00
Allowance For Doubtful Accounts Receivable
-836.00
Inventory
1,787.00
Prepaid Assets
—
Other Current Assets
2,374.00
Total Non Current Assets
46,040.00
Net PPE
5,317.00
Gross PPE
7,766.00
Accumulated Depreciation
-2,449.00
Properties
0.00
Land And Improvements
561.00
Buildings And Improvements
4,328.00
Machinery Furniture Equipment
1,069.00
Construction In Progress
661.00
Other Properties
1,147.00
Goodwill And Other Intangible Assets
34,768.00
Goodwill
8,314.00
Other Intangible Assets
26,454.00
Investments And Advances
1,163.00
Non Current Deferred Assets
—
Non Current Deferred Taxes Assets
—
Other Non Current Assets
4,792.00
Total Liabilities Net Minority Interest
39,376.00
Current Liabilities
11,280.00
Payables And Accrued Expenses
5,560.00
Payables
1,758.00
Accounts Payable
550.00
Current Accrued Expenses
3,802.00
Pensionand Other Post Retirement Benefit Plans Current
1,201.00
Total Tax Payable
1,208.00
Income Tax Payable
1,208.00
Current Debt And Capital Lease Obligation
1,798.00
Current Debt
1,798.00
Other Current Liabilities
2,334.00
Total Non Current Liabilities Net Minority Interest
28,096.00
Long Term Debt And Capital Lease Obligation
23,189.00
Long Term Debt
23,189.00
Tradeand Other Payables Non Current
2,039.00
Non Current Deferred Liabilities
1,588.00
Non Current Deferred Taxes Liabilities
1,588.00
Other Non Current Liabilities
1,280.00
Stockholders Equity
22,833.00
Common Stock Equity
22,833.00
Capital Stock
1.00
Common Stock
1.00
Preferred Stock
0.00
Share Issued
1,246.04
Ordinary Shares Number
1,246.04
Treasury Shares Number
0.00
Additional Paid In Capital
6,500.00
Retained Earnings
16,304.00
Gains Losses Not Affecting Retained Earnings
28.00
Minority Interest
-84.00
Other Equity Adjustments
28.00
Total Equity Gross Minority Interest
22,749.00
Total Capitalization
46,022.00
Working Capital
4,805.00
Invested Capital
47,820.00
Total Debt
24,987.00
Net Debt
18,902.00
Net Tangible Assets
-11,935.00
Tangible Book Value
-11,935.00
Available For Sale Securities
1,163.00
Current Provisions
387.00
Investmentin Financial Assets
1,163.00
Line Item Trend 2025-12-31 2024-12-31 2023-12-31 2022-12-31
Operating Cash Flow
10,019.00
-7.47%
10,828.00
+35.25%
8,006.00
-11.75%
9,072.00
Cash Flow From Continuing Operating Activities
10,019.00
-7.47%
10,828.00
+35.27%
8,005.00
-11.76%
9,072.00
Net Income From Continuing Operations
8,510.00
+1672.92%
480.00
-91.45%
5,613.00
+22.93%
4,566.00
Depreciation Amortization Depletion
2,760.00
-0.25%
2,767.00
+2.75%
2,693.00
+28.06%
2,103.00
Depreciation
370.00
-2.89%
381.00
+7.63%
354.00
+9.60%
323.00
Amortization Cash Flow
2,390.00
+0.17%
2,386.00
+2.01%
2,339.00
+31.40%
1,780.00
Depreciation And Amortization
2,760.00
-0.25%
2,767.00
+2.75%
2,693.00
+28.06%
2,103.00
Amortization Of Intangibles
2,390.00
+0.17%
2,386.00
+2.01%
2,339.00
+31.40%
1,780.00
Other Non Cash Items
1,504.00
-70.02%
5,016.00
+153.08%
1,982.00
+14.97%
1,724.00
Stock Based Compensation
894.00
+7.07%
835.00
+9.01%
766.00
+20.25%
637.00
Asset Impairment Charge
590.00
-85.89%
4,180.00
+8260.00%
50.00
-98.15%
2,700.00
Deferred Tax
160.00
+108.68%
-1,844.00
-91.68%
-962.00
+38.02%
-1,552.00
Deferred Income Tax
160.00
+108.68%
-1,844.00
-91.68%
-962.00
+38.02%
-1,552.00
Operating Gains Losses
-451.00
-264.60%
274.00
+64.07%
167.00
-74.58%
657.00
Gain Loss On Investment Securities
-451.00
-264.60%
274.00
+64.07%
167.00
-74.58%
657.00
Change In Working Capital
-3,948.00
-348.64%
-880.00
+61.79%
-2,303.00
-30.63%
-1,763.00
Change In Receivables
-367.00
-364.03%
139.00
-11.46%
157.00
+138.67%
-406.00
Changes In Account Receivables
-367.00
-364.03%
139.00
-11.46%
157.00
+138.67%
-406.00
Change In Inventory
-1,036.00
-143.19%
-426.00
+49.41%
-842.00
-171.61%
-310.00
Change In Prepaid Assets
-311.00
-20.08%
-259.00
-764.10%
39.00
+129.10%
-134.00
Change In Payables And Accrued Expense
-126.00
-131.66%
398.00
+258.56%
111.00
+120.22%
-549.00
Change In Accrued Expense
6.00
-94.44%
108.00
-76.42%
458.00
+159.10%
-775.00
Change In Payable
-132.00
-145.52%
290.00
+183.57%
-347.00
-253.54%
226.00
Change In Account Payable
-132.00
-145.52%
290.00
+183.57%
-347.00
-253.54%
226.00
Change In Other Working Capital
-2,108.00
-187.98%
-732.00
+58.60%
-1,768.00
-385.71%
-364.00
Investing Cash Flow
-4,793.00
-38.97%
-3,449.00
-52.27%
-2,265.00
+8.15%
-2,466.00
Cash Flow From Continuing Investing Activities
-4,794.00
-39.00%
-3,449.00
-52.21%
-2,266.00
+8.11%
-2,466.00
Net PPE Purchase And Sale
-563.00
-7.65%
-523.00
+10.60%
-585.00
—
Purchase Of PPE
-563.00
-7.65%
-523.00
+10.60%
-585.00
—
Capital Expenditure
-563.00
-7.65%
-523.00
+10.60%
-585.00
+19.64%
-728.00
Capital Expenditure Reported
—
-523.00
+10.60%
-585.00
+19.64%
-728.00
Net Investment Purchase And Sale
-3,163.00
-270.42%
1,856.00
+451.52%
-528.00
-980.00%
60.00
Purchase Of Investment
-4,072.00
-453.26%
-736.00
+68.97%
-2,372.00
-22.14%
-1,942.00
Sale Of Investment
909.00
-64.93%
2,592.00
+40.56%
1,844.00
-7.89%
2,002.00
Net Business Purchase And Sale
-1,070.00
+77.89%
-4,840.00
-320.14%
-1,152.00
+35.89%
-1,797.00
Purchase Of Business
-1,070.00
+77.89%
-4,840.00
-320.14%
-1,152.00
+35.89%
-1,797.00
Net Other Investing Changes
3.00
-94.83%
58.00
—
-1.00
Financing Cash Flow
-7,745.00
-125.60%
-3,433.00
+33.01%
-5,125.00
+20.78%
-6,469.00
Cash Flow From Continuing Financing Activities
-7,745.00
-125.60%
-3,433.00
+33.03%
-5,126.00
+20.76%
-6,469.00
Net Issuance Payments Of Debt
-1,788.00
-219.68%
1,494.00
+653.33%
-270.00
+82.00%
-1,500.00
Issuance Of Debt
0.00
-100.00%
3,464.00
+74.95%
1,980.00
0.00
Repayment Of Debt
-1,788.00
+9.24%
-1,970.00
+12.44%
-2,250.00
-50.00%
-1,500.00
Long Term Debt Issuance
0.00
-100.00%
3,464.00
+74.95%
1,980.00
0.00
Long Term Debt Payments
-1,788.00
+9.24%
-1,970.00
+12.44%
-2,250.00
-50.00%
-1,500.00
Net Long Term Debt Issuance
-1,788.00
-219.68%
1,494.00
+653.33%
-270.00
+82.00%
-1,500.00
Net Common Stock Issuance
-1,514.00
-107.97%
-728.00
+5.21%
-768.00
+29.35%
-1,087.00
Common Stock Payments
-1,922.00
-67.13%
-1,150.00
-15.00%
-1,000.00
+28.37%
-1,396.00
Common Stock Dividend Paid
-4,003.00
-2.17%
-3,918.00
-2.86%
-3,809.00
-2.70%
-3,709.00
Cash Dividends Paid
-4,003.00
-2.17%
-3,918.00
-2.86%
-3,809.00
-2.70%
-3,709.00
Repurchase Of Capital Stock
-1,922.00
-67.13%
-1,150.00
-15.00%
-1,000.00
+28.37%
-1,396.00
Net Other Financing Charges
-440.00
-56.58%
-281.00
-1.08%
-278.00
-60.69%
-173.00
Changes In Cash
-2,519.00
-163.84%
3,946.00
+540.58%
616.00
+349.64%
137.00
Effect Of Exchange Rate Changes
92.00
+330.00%
-40.00
-170.18%
57.00
+190.48%
-63.00
Beginning Cash Position
9,991.00
+64.19%
6,085.00
+12.44%
5,412.00
+1.39%
5,338.00
End Cash Position
7,564.00
-24.29%
9,991.00
+64.19%
6,085.00
+12.44%
5,412.00
Free Cash Flow
9,456.00
-8.24%
10,305.00
+38.86%
7,421.00
-11.06%
8,344.00
Interest Paid Supplemental Data
1,036.00
+8.94%
951.00
+6.73%
891.00
-1.76%
907.00
Income Tax Paid Supplemental Data
3,215.00
+15.69%
2,779.00
-30.35%
3,990.00
+27.23%
3,136.00
Change In Income Tax Payable
—
—
—
-568.00
Change In Tax Payable
—
—
—
-568.00
Common Stock Issuance
408.00
-3.32%
422.00
+81.90%
232.00
-24.92%
309.00
Issuance Of Capital Stock
408.00
-3.32%
422.00
+81.90%
232.00
-24.92%
309.00
SEC Filings

Recent 10-K, 10-Q, 8-K, and Form 4 (insider) filings.

Trades
Date User Broker Pattern Type Position Size Entry Price Trade P&L Status
Posts
Published Title Author Category